US 11,925,657 B2
Formulations and methods for treating conditions of the eye
Paul Badawi, Atherton, CA (US); and David Y. Badawi, Glenview, IL (US)
Assigned to SIGHT SCIENCES, INC., Menlo Park, CA (US)
Filed by Sight Sciences, Inc., Menlo Park, CA (US)
Filed on Dec. 23, 2022, as Appl. No. 18/088,347.
Application 18/088,347 is a continuation of application No. 17/868,696, filed on Jul. 19, 2022, granted, now 11,554,134.
Application 17/868,696 is a continuation of application No. 17/534,349, filed on Nov. 23, 2021, granted, now 11,419,886, issued on Aug. 23, 2022.
Claims priority of provisional application 63/254,958, filed on Oct. 12, 2021.
Claims priority of provisional application 63/117,393, filed on Nov. 23, 2020.
Prior Publication US 2023/0210878 A1, Jul. 6, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/7052 (2006.01); A61K 9/00 (2006.01); A61K 31/194 (2006.01); A61K 31/7048 (2006.01); A61K 47/10 (2017.01); A61P 27/02 (2006.01); A61P 27/04 (2006.01)
CPC A61K 31/7052 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0048 (2013.01); A61K 31/194 (2013.01); A61K 31/7048 (2013.01); A61K 47/10 (2013.01); A61P 27/02 (2018.01); A61P 27/04 (2018.01)] 27 Claims
 
1. A method for treating dry eye disease comprising:
administering a pharmaceutical formulation comprising between about 1% and about 20% azelaic acid,
wherein the pharmaceutical formulation is administered to an external surface of the lower eyelid below lower lashes daily for at least 1 month, and wherein administering the pharmaceutical formulation reduces a symptom of dry eye disease.